Evidence map›Paper›PMID 16106073›Full record

ReviewImmunologic research2005

Pathogenesis and treatment of human T-cell leukemia virus infection.

Lee Ratner

Open access · greenAbstract readReview
In one paragraph

Review in Immunologic research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Lee RatnerDivision of Molecular Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. lratner@im.wustl.edu
Washington University in St. Louis · US

Funding

Role of Inflammation in Tax-mediated TumorigenesisP01CA100730 · NCI · WASHINGTON UNIVERSITY · PI Malachi Griffith · 2003 to 2026
$44.8M
PROLIFERATIVE EFFECTS OF HTLV1R01CA063417 · NCI · WASHINGTON UNIVERSITY · PI RATNER, LEE · 1995 to 2017
$3.7M
CHEMO/ANTIRETROVIRAL THERAPY FOR HTLV1 ATLLR21CA093062 · NCI · WASHINGTON UNIVERSITY · PI RATNER, LEE · 2001 to 2002
$608k
NCI NIH HHS P01 CA100730NCI NIH HHS R01 CA063417NCI NIH HHS R21 CA093062
6 · The paper itself

Abstract

The pathogenesis of human T-cell leukemia virus (HTLV)-induced adult T-cell leukemia-lymphoma (ATLL) was explored using an infectious molecular viral clone and a transgenic mouse model. Activation of nuclear factor-kappaB by the HTLV transcriptional transactivator protein Tax was found to be important for lymphocyte immortalization and tumorigenesis. Interferon-gamma regulates tumor development owing primarily to angiostatic effects. Translational clinical studies of chemotherapy, interferon-alpha, and nucleoside reverse transcriptase inhibitors have also assisted in identifying the pathogenic features of ATLL.

Indexed as

AnimalsAntineoplastic AgentsAnti-Retroviral AgentsDisease Models, AnimalGene Products, taxGenes, pXHTLV-I InfectionsHumansHuman T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellMiceMice, TransgenicNF-kappa BAntineoplastic AgentsAnti-Retroviral AgentsGene Products, taxNF-kappa B

Identifiers

PMID16106073
PMCPMC2652731
OpenAlexW1964569772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.